§ Claim under review · Study
"A small study (Erhardt et al., 2025, npj Parkinson's Disease) found that intermittent hypercapnia (alternating 5% CO2 and normal air in 35-second cycles) increased blood levels of amyloid-beta and phosphorylated tau after ~30 minutes, suggesting the treatment may help clear Alzheimer's-linked proteins from the brain via the glymphatic system in 10 participants (5 with Parkinson's, 5 healthy older adults)." Accompanying post caption: "Scientists have found that controlled bursts of carbon dioxide may help the brain clear proteins linked to Alzheimer's disease."
Verdict
Mostly accurate
Confidence
MediumSummary
The study being shared is real. Erhardt and colleagues published it in npj Parkinson's Disease in November 2025, and the abstract confirms that about 30 minutes of intermittent carbon dioxide exposure, given as three 10-minute sessions, was followed by increased blood levels of amyloid beta and phosphorylated tau along with alpha-synuclein and other brain-derived proteins. The authors do interpret this as evidence that the brain's waste clearance system was moving these proteins out. Two important caveats: this was a Parkinson's disease study, not an Alzheimer's study, and finding proteins in the blood shows movement, not proof that the brain's protein burden actually went down. The participant numbers in the post could not be confirmed, and one secondary report describes a considerably larger imaging group than the 10 people the post mentions. No clinical benefit of any kind was measured, so nothing here shows that breathing CO2 prevents or treats any disease. The safety warning in the post is worth keeping: this was a low-level, medically supervised exposure, and self-experimentation with CO2 is not safe.
The readings
key figures from the evidencetotal duration of intermittent hypercapnia exposure
sample size claimed in the post (5 PD, 5 healthy)
older adults in imaging cohort per secondary source, conflicts with post
Why this verdict
Evidence
The paper is real and the citation is correct. The published abstract states that a failure of the glymphatic pathway to clear brain byproducts implicated in neurodegeneration may contribute to Parkinson's pathophysiology, and that the glymphatic pathway relies on vasomotion, the rhythmic constriction and dilation of blood vessels, to drive cerebrospinal fluid through the interstitial space . The study reports that intermittent hypercapnia, exposure to low levels of CO2 in ON-OFF cycles, elicited vasomotion-induced cerebrospinal fluid inflow in both healthy controls and individuals with Parkinson's disease, and that the magnitude of this inflow was reduced in Parkinson's patients relative to healthy controls. On the biomarker result, the abstract states that intermittent hypercapnia, administered in three 10-minute sessions totaling approximately 30 minutes, increased the appearance of total alpha-synuclein, neurofilament light, glial fibrillary acidic protein, amyloid beta 1-42, amyloid beta 1-40, and phosphorylated tau 217 in the plasma of both healthy controls and individuals with Parkinson's disease, which the authors say suggests intermittent hypercapnia can be used to clear potentially toxic brain byproducts from the brain, highlighting its potential use as a disease modifying treatment .
The senior author is described as having led studies to evaluate how intermittent breathing of CO2 could be used to dilate and constrict brain arteries and drive the movement of cerebrospinal fluid through brain tissue to clear unwanted proteins , and the institutional release notes the rationale that the glymphatic pathway is most active during deep sleep, that Parkinson's patients often experience sleep disturbances that may impair this waste removal process, and that a prior study found reduced and delayed cerebrovascular response to intermittent CO2 in Parkinson's patients . The author characterizes the work cautiously: "The results of this study represent an initial observation that..." and describes the findings as suggesting that intermittent hypercapnia mimics the slow cerebrovascular and cerebrospinal fluid oscillations observed during sleep and is associated with increased clearance of neurodegeneration-related proteins .
Findings
✓ What's accurate 7
- The paper exists exactly as cited: Erhardt et al., npj Parkinson's Disease, 2025, volume 11, article 334.
- The intervention is intermittent hypercapnia, cyclic exposure to elevated CO2 alternating with normal air.
- Roughly 30 minutes of exposure, delivered as three 10-minute sessions, is accurate.
- Plasma amyloid beta (both 1-40 and 1-42) and phosphorylated tau 217 did increase after the intervention, alongside alpha-synuclein, NfL, and GFAP.
- The glymphatic clearance interpretation is the authors' own stated interpretation, not an invention of the post.
- The 35-second cycle length is corroborated by secondary reporting.
- The post's caveats are largely correct: the study did not test prevention of Alzheimer's, memory improvement, or symptom reduction.
≈ What's misleading 4
- Framing shift: this is a Parkinson's disease study. Its primary targets were Parkinson's-related clearance and alpha-synuclein. Recasting it as an Alzheimer's finding foregrounds two of six measured proteins and attaches the result to a disease the study did not enroll patients for. This is subgroup and endpoint reframing.
- Inference presented as outcome: rising plasma protein levels are an indirect proxy. The study shows proteins appearing in blood, not that brain burden decreased. Alternative explanations such as altered blood brain barrier permeability or hemodynamic and volume shifts from CO2 exposure are not excluded by the abstract-level evidence. The post's phrase "may help clear" is appropriately hedged, but the image headline as described is not.
- Dose characterization: the abstract describes "low levels of CO2," while the caption warns about "concentrated CO2." The safety warning itself is reasonable, but it mischaracterizes what was administered.
- "Treatment" framing: no clinical benefit of any kind was measured. There is no evidence here that this is a treatment for anything.
? What's uncertain 4
- Sample size. The post says 10 participants, 5 with Parkinson's and 5 healthy. A secondary source reports 63 participants, 30 with Parkinson's, for the imaging component. I could not retrieve the paper's methods to reconcile these. The 5 and 5 split may describe only a blood-sampling subgroup, or it may simply be wrong.
- The exact CO2 concentration in this specific protocol. 5 percent is plausible given related protocols but unconfirmed here.
- Whether there was a control or sham condition, and the statistical significance and effect size of each biomarker change.
- Whether the plasma increases were sustained, transient, or clinically meaningful in any way.
Sources
5 of 8 linked to recordsErhardt EB, Mayer AR, Lin HC, et al., "The influence of intermittent hypercapnia on cerebrospinal fluid flow and clearance in Parkinson's disease and healthy older adults," npj Parkinson's Disease 2025;11(1):334, doi:10.1038/s41531-025-01179-6
PubMed record for the same paper, PMID 41271795
University of Groningen research portal abstract record (full abstract text)
EurekAlert press release from the University of New Mexico / Mind Research Network
ClinicalTrials.gov NCT07674264, a related registered trial of acute intermittent hypercapnia in Parkinson's
U.S. Medicine coverage with direct quotes from the senior author
Parkinson's NSW summary article
Technology Networks, Parkinson's News Today, Medindia, Yahoo Health items